Recent updates on targeting the molecular mediators of NAFLD
AbstractNonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common disease worldwide in an era of rapid economic growth. NAFLD is a multifactorial disease, involving multiple genetic, metabolic, and environmental factors, and is closely associated with metabolic syndrome, obesity, and cardiovascular disease. NAFLD can be classified into nonalcoholic fatty liver disease (NAFL) and nonalcoholic steatohepatitis (NASH), which can both progress to cirrhosis and even hepatocellular carcinoma (HCC). Due to the enormous burden of NAFLD and its complications, no FDA-approved drugs for the treatment of NAFLD are on the market, and therapeutic targets and drug therapies are being actively investigated. In view of the various pathological mechanisms of NAFLD, numbers of preclinical studies and clinical trials have made rapid progress. This review mainly summarizes the most recently characterized mechanisms and therapeutic targets in each mechanism of NAFLD, focusing on the mechanism and application potential.
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Cirrhosis | Clinical Trials | Eating Disorders & Weight Management | Environmental Health | Fatty Liver Disease (FLD) | Genetics | Heart | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Molecular Biology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology